Skip to main content
. 2015 May 14;10(5):e0127361. doi: 10.1371/journal.pone.0127361

Fig 2. Ganetespib treatment suppresses autoantibody production.

Fig 2

(A) Anti-chromatin autoantibody titers measured during twice—weekly dosing with vehicle or 50 mg/kg ganetespib for 14 weeks. Inverse titers are shown. (B) Fold-changes in circulating anti-dsDNA levels were determined following the 14 week treatment period. (C) Percentage changes in total serum IgG levels assessed after the 14 week treatment period. Serum changes in age-matched non-lupus MRL/Mp mice are included as a control.